JUN 20, 2018 6:23 AM PDT

New Drug 'Moxidectin' for River Blindness

WRITTEN BY: Nouran Amin

A new treatment to help eliminate a neglected tropical disease was developed thanks in part to an incentive program devised by researchers at Duke University.

Moxidectin, a macrocyclic lactone created by the drug company Medicines Development for Global Health, was recently approved by The U.S. Food and Drug Administration.

Moxidectin seeks to treat helminthic infections that affect more than 15 million people worldwide. The firm will be awarded a voucher for priority review of another drug, under a system first proposed by David Ridley, a professor at Duke University’s Fuqua School of Business, Henry Grabowski of the Duke Department of Economics, and Jeffrey Moe, of the Duke Global Health Institute.

“With a new treatment, we’re one step closer to eliminating river blindness,” Ridley said. “And the developer is a non-profit company,” explains David Ridley, a professor at Duke University’s Fuqua School of Business.

River blindness, or onchocerciasis, is typically found in economically-distressed areas in sub-Saharan Africa. The clinical trials published in The Lancet medical journal found that moxidectin to be more effective in treating river disease than any current treatment.

Moxidectin is a anthelmintic medicine that targets the parasite's glutamate-gated chloride ion channels. These ion channels are crucial to the function of invertebrate nerve and muscle cells. Moxidectin has activity against O. volvulus microfilariae, the parasite involved in river blindness disease, but does not have an effect on adult O. volvulus parasites.

 

Individuals with river blindness administered moxidectin had adverse events consistent with those associated with efficacy. The nature and severity of these effects from moxidectin recipients were similar to another drug known as ivermectin.

 

Eosinophilia, pruritus, musculoskeletal pain, headache, lymphopenia, tachycardia, rash, abdominal pain, hypotension, pyrexia, leukocytosis, influenza-like illness, neutropenia, cough, lymph node pain, dizziness, diarrhea, hyponatremia and peripheral swelling; were are all considered to be the most common adverse reactions.

 

However, the efficacy of repeat administrations of moxidectin have yet to be examined. Moxidectin is given as 2 mg tablets for administration as an 8 mg dose per oral to patients at least 12 years of age with O. volvulus infection.

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 27, 2020
Cannabis Sciences
THC Shows Promise in Treating Severe Cases of COVID-19
SEP 27, 2020
THC Shows Promise in Treating Severe Cases of COVID-19
Over the last few months, various headlines have emerged suggesting the potential for cannabinoids, and in particular, c ...
SEP 30, 2020
Cancer
Chemokines Could be the Key in Controlling Glioma Stem Cells
SEP 30, 2020
Chemokines Could be the Key in Controlling Glioma Stem Cells
The transformation of a healthy cell into a cancerous one often comes with a slew of cellular signaling changes.  T ...
OCT 21, 2020
Microbiology
The First Treatment for Ebola is Approved by FDA
OCT 21, 2020
The First Treatment for Ebola is Approved by FDA
Ebola virus can pass from animals to humans, and between people. Rarely, it causes outbreaks but when it does, they can ...
OCT 11, 2020
Drug Discovery & Development
Treating Connective Tissue Disorders
OCT 11, 2020
Treating Connective Tissue Disorders
Collaborative research efforts are geared to improving disease that affects connective tissues via innovative drug deliv ...
NOV 12, 2020
Technology
The Crossover of Virtual Reality and Drug Discovery
NOV 12, 2020
The Crossover of Virtual Reality and Drug Discovery
Researchers have recently developed a unique virtual reality (VR) tool that can help in drug development? Particularly, ...
NOV 22, 2020
Cannabis Sciences
Public Believes CBD is Cure-All Despite Lack of Evidence
NOV 22, 2020
Public Believes CBD is Cure-All Despite Lack of Evidence
Many people think that cannabidiol (CBD), a non-psychoactive compound in cannabis, can reduce symptoms from various cond ...
Loading Comments...